Percentage of participants achieving sustained virologic response SVR12 12 weeks after the last actual dose of study drug [clinicaltrials_resource:a7ac853151293d46d001eaf672c79ae2]
Percentage of participants with HCV RNA < LLOQ 12 weeks post-treatment.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Percentage of participants achieving sustained virologic response SVR12 12 weeks after the last actual dose of study drug [clinicaltrials_resource:a7ac853151293d46d001eaf672c79ae2]
Percentage of participants with HCV RNA < LLOQ 12 weeks post-treatment.
Bio2RDF identifier
a7ac853151293d46d001eaf672c79ae2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a7ac853151293d46d001eaf672c79ae2
measure [clinicaltrials_vocabulary:measure]
Percentage of participants achieving sustained virologic response SVR12
time frame [clinicaltrials_vocabulary:time-frame]
12 weeks after the last actual dose of study drug
description
Percentage of participants with HCV RNA < LLOQ 12 weeks post-treatment.
identifier
clinicaltrials_resource:a7ac853151293d46d001eaf672c79ae2
title
Percentage of participants ach ...... last actual dose of study drug
@en
type
label
Percentage of participants ach ...... c853151293d46d001eaf672c79ae2]
@en